Hüseyin Yusuf Yıldız
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hüseyin Yusuf Yıldız has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Mustafa Onur Karaca
Department of Orthopedics and Traumatology, Ankara University Faculty of Medicine, Ankara, Türkiye
13 shared publications - Kerem Başarır
Department of Orthopedics and Traumatology, Private Orthopedic Surgeon, Ankara, Türkiye
9 shared publications - Mustafa Özyıldıran
Department of Orthopedics and Traumatology, Sandıklı State Hospital, Afyonkarahisar, Turkey
7 shared publications - Abdullah Merter
Department of Orthopedics and Traumatology, Ankara University Faculty of Medicine, Ankara, Turkey
4 shared publications - Emre Anıl Özbek
Department of Orthopaedic Surgery Ankara University Ankara Turkey
3 shared publications - Ibrahim Halil Demir
Department of Orthopaedics and Traumatology, Gaziantep City Hospital, Gaziantep 27500, Türkiye
3 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7885
Preoperative Inflammatory Markers in Relation to the Malignant Potential of Cartilaginous Tumors: A Retrospective Cohort Study
Background: The definitive diagnosis of cartilaginous tumors remains challenging because imaging and biopsy findings may not reliably distinguish low-grade from high-grade lesions. Consequently, the final diagnosis is often established only after surgical excision and histopathological examination. Inflammatory biomarkers derived from routine peripheral blood tests have emerged as potential adjunctive tools for tumor characterization, but their role in cartilaginous tumors remains unclear. Questions/Purposes: (1) Are preoperative inflammatory markers different between low-grade and high-grade cartilaginous tumors? (2) Which inflammatory markers are associated with high-grade (versus low-grade) cartilaginous tumors? (3) What is the diagnostic performance of the pan-immune inflammation value (PIV) in predicting high-grade cartilaginous tumors? Patients and Methods: We retrospectively reviewed 67 patients who underwent surgery for cartilaginous tumors between January 2022 and July 2025 and received definitive histopathological diagnoses. Patients were divided into two groups according to tumor grade. Group A consisted of enchondroma (n = 9), atypical cartilaginous tumor (ACT) (n = 13), and Grade 1 chondrosarcoma (n = 14), whereas Group B consisted of Grade 2 (n = 19) and Grade 3 chondrosarcoma (n = 12). Preoperative peripheral blood inflammatory markers, including white blood cell count (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), mean platelet volume (MPV), red blood cell distribution width (RDW), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and pan-immune inflammation value (PIV), were compared between groups. Receiver operating characteristic (ROC) analysis was performed to evaluate the diagnostic performance of significant biomarkers. Results: Baseline demographic and clinical characteristics were comparable between groups. Patients with high-grade chondrosarcoma (Group B) demonstrated higher CRP (6.35 ± 5.25 versus 4.02 ± 3.33; p = 0.030), PLR (198.08 ± 98.83 versus 139.11 ± 73.76; p = 0.016), SII (728.33 ± 177.26 versus 526.50 ± 126.17; p = 0.001), SIRI (2.01 ± 0.72 versus 1.40 ± 0.62; p = 0.001), and PIV (629.68 ± 125.19 versus 295.00 ± 111.48; p = 0.001) compared with Group A. ROC analysis showed that PIV had the highest diagnostic accuracy, with a cutoff value greater than 461.5 yielding a sensitivity of 96.8% and a specificity of 97.2% for identifying high-grade malignancy (p < 0.001). Conclusions: Preoperative inflammatory markers, particularly SII, SIRI, and PIV, were associated with high-grade cartilaginous tumors; differences in CRP and PLR did not survive correction for multiple comparisons. Among these markers, PIV demonstrated excellent discriminatory ability for distinguishing high-grade from low-grade cartilaginous tumors. These findings suggest that PIV may serve as a readily available and low-cost adjunctive biomarker in the preoperative evaluation of cartilaginous tumors. Further prospective studies are warranted to validate its clinical utility and determine its role alongside established radiological and histopathological assessment methods. Level of Evidence: Level III, diagnostic study (retrospective comparative cohort study).
- 13 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7885
Open AccessPreoperative Inflammatory Markers in Relation to the Malignant Potential of Cartilaginous Tumors: A Retrospective Cohort Study
Background: The definitive diagnosis of cartilaginous tumors remains challenging because imaging and biopsy findings may not reliably distinguish low-grade from high-grade lesions. Consequently, the final diagnosis is often established only after surgical excision and histopathological examination. Inflammatory biomarkers derived from routine peripheral blood tests have emerged as potential adjunctive tools for tumor characterization, but their role in cartilaginous tumors remains unclear. Questions/Purposes: (1) Are preoperative inflammatory markers different between low-grade and high-grade cartilaginous tumors? (2) Which inflammatory markers are associated with high-grade (versus low-grade) cartilaginous tumors? (3) What is the diagnostic performance of the pan-immune inflammation value (PIV) in predicting high-grade cartilaginous tumors? Patients and Methods: We retrospectively reviewed 67 patients who underwent surgery for cartilaginous tumors between January 2022 and July 2025 and received definitive histopathological diagnoses. Patients were divided into two groups according to tumor grade. Group A consisted of enchondroma (n = 9), atypical cartilaginous tumor (ACT) (n = 13), and Grade 1 chondrosarcoma (n = 14), whereas Group B consisted of Grade 2 (n = 19) and Grade 3 chondrosarcoma (n = 12). Preoperative peripheral blood inflammatory markers, including white blood cell count (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), mean platelet volume (MPV), red blood cell distribution width (RDW), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and pan-immune inflammation value (PIV), were compared between groups. Receiver operating characteristic (ROC) analysis was performed to evaluate the diagnostic performance of significant biomarkers. Results: Baseline demographic and clinical characteristics were comparable between groups. Patients with high-grade chondrosarcoma (Group B) demonstrated higher CRP (6.35 ± 5.25 versus 4.02 ± 3.33; p = 0.030), PLR (198.08 ± 98.83 versus 139.11 ± 73.76; p = 0.016), SII (728.33 ± 177.26 versus 526.50 ± 126.17; p = 0.001), SIRI (2.01 ± 0.72 versus 1.40 ± 0.62; p = 0.001), and PIV (629.68 ± 125.19 versus 295.00 ± 111.48; p = 0.001) compared with Group A. ROC analysis showed that PIV had the highest diagnostic accuracy, with a cutoff value greater than 461.5 yielding a sensitivity of 96.8% and a specificity of 97.2% for identifying high-grade malignancy (p < 0.001). Conclusions: Preoperative inflammatory markers, particularly SII, SIRI, and PIV, were associated with high-grade cartilaginous tumors; differences in CRP and PLR did not survive correction for multiple comparisons. Among these markers, PIV demonstrated excellent discriminatory ability for distinguishing high-grade from low-grade cartilaginous tumors. These findings suggest that PIV may serve as a readily available and low-cost adjunctive biomarker in the preoperative evaluation of cartilaginous tumors. Further prospective studies are warranted to validate its clinical utility and determine its role alongside established radiological and histopathological assessment methods. Level of Evidence: Level III, diagnostic study (retrospective comparative cohort study).
- Open Access
- 19 September 2026
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 9 (5) , 1319-1327
Association of pre-biopsy inflammatory indices with prosthetic joint infection after megaprosthetic reconstruction for osteosarcoma
Aims: Prosthetic joint infection (PJI) is a challenging disease associated with substantial patient disability and high treatment costs. This study aimed to evaluate the association between inflammatory markers measured in pre-biopsy blood samples and PJI in patients with osteosarcoma.Methods: This retrospective study included 48 patients with osteosarcoma who underwent neoadjuvant chemotherapy followed by resection prosthesis at a tertiary care centre between January 2020 and October 2023. PJI was observed in 7 patients (14.6%) during the 12-month follow-up period, and the diagnosis was established in accordance with the 2018 Musculoskeletal Infection Society criteria. Blood samples collected before biopsy were analyzed for a comprehensive set of inflammatory markers, including white blood cell count, erythrocyte sedimentation rate, C-reactive protein, mean platelet volume, red blood cell distribution width, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), Systemic Immune-Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), and pan-immune-inflammation value.Results: PJI occurred in 7 patients (14.6%), while 41 patients (85.4%) did not develop PJI. There were no significant differences between the two groups in terms of age, body-mass index, gender, affected extremity, or prosthesis location (p>0.05). Patients with PJI had significantly higher NLR (3.9±0.8 vs. 2.0±0.7, p
- 19 September 2026
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 9 (5) , 1319-1327
Open AccessAssociation of pre-biopsy inflammatory indices with prosthetic joint infection after megaprosthetic reconstruction for osteosarcoma
Aims: Prosthetic joint infection (PJI) is a challenging disease associated with substantial patient disability and high treatment costs. This study aimed to evaluate the association between inflammatory markers measured in pre-biopsy blood samples and PJI in patients with osteosarcoma.Methods: This retrospective study included 48 patients with osteosarcoma who underwent neoadjuvant chemotherapy followed by resection prosthesis at a tertiary care centre between January 2020 and October 2023. PJI was observed in 7 patients (14.6%) during the 12-month follow-up period, and the diagnosis was established in accordance with the 2018 Musculoskeletal Infection Society criteria. Blood samples collected before biopsy were analyzed for a comprehensive set of inflammatory markers, including white blood cell count, erythrocyte sedimentation rate, C-reactive protein, mean platelet volume, red blood cell distribution width, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), Systemic Immune-Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), and pan-immune-inflammation value.Results: PJI occurred in 7 patients (14.6%), while 41 patients (85.4%) did not develop PJI. There were no significant differences between the two groups in terms of age, body-mass index, gender, affected extremity, or prosthesis location (p>0.05). Patients with PJI had significantly higher NLR (3.9±0.8 vs. 2.0±0.7, p
- Open Access
- 17 June 2026
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 27 (1)
Bone versus soft tissue hydatid disease: a retrospective comparative cohort study
Musculoskeletal hydatid disease is uncommon and often mimics neoplastic lesions. Comparative evidence between bone and soft tissue involvement remains limi
- 17 June 2026
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 27 (1)
Open AccessBone versus soft tissue hydatid disease: a retrospective comparative cohort study
Musculoskeletal hydatid disease is uncommon and often mimics neoplastic lesions. Comparative evidence between bone and soft tissue involvement remains limi
- 27 April 2026
- Published by Kirikkale Universitesi Tip Fakultesi Dergisi in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
- Vol. 28 (1) , 102-106
FUNCTIONAL OUTCOMES OF PATIENTS TREATED WITH MODULAR TUMOR RESECTION PROSTHESIS FOLLOWING PROXIMAL HUMERUS TUMOR
Objectives: This study aims to evaluate the functional outcomes of patients undergoing hemiarthroplasty with modular tumor prostheses for proximal humeral tumors. Material and Methods: A total of 28 patients were included in the study, with an average follow-up of 71.11 months. The mean age of participants was 47.8 years, and the cohort included various tumor types, including osteosarcoma and chondrosarcoma. Functional outcomes were assessed using the Modified Musculoskeletal Tumor Society evaluation system, the American Shoulder and Elbow Surgeons score, and the Visual Analog Scale for pain.Results: The postoperative results demonstrated an average Modified Musculoskeletal Tumor Society score of 21.68 and an American Shoulder and Elbow Surgeons score of 52.71, reflecting substantial improvements in both shoulder function and pain management. Notably, the Visual Analog Scale scores decreased significantly, from a preoperative average of 6.57 to a postoperative average of 3.79. This reduction in pain intensity indicates that patients experienced a marked alleviation of discomfort following the surgical intervention.Conclusion: Modular tumor prosthesis represents a reliable and effective treatment option for proximal humerus tumors. Although low infection and recurrence rates were noted, further research with larger sample sizes and longer follow-up is necessary to fully understand the long-term durability of the prosthesis and its potential complications, particularly in younger, more active patients.
- 27 April 2026
- Published by Kirikkale Universitesi Tip Fakultesi Dergisi in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
- Vol. 28 (1) , 102-106
FUNCTIONAL OUTCOMES OF PATIENTS TREATED WITH MODULAR TUMOR RESECTION PROSTHESIS FOLLOWING PROXIMAL HUMERUS TUMOR
Objectives: This study aims to evaluate the functional outcomes of patients undergoing hemiarthroplasty with modular tumor prostheses for proximal humeral tumors. Material and Methods: A total of 28 patients were included in the study, with an average follow-up of 71.11 months. The mean age of participants was 47.8 years, and the cohort included various tumor types, including osteosarcoma and chondrosarcoma. Functional outcomes were assessed using the Modified Musculoskeletal Tumor Society evaluation system, the American Shoulder and Elbow Surgeons score, and the Visual Analog Scale for pain.Results: The postoperative results demonstrated an average Modified Musculoskeletal Tumor Society score of 21.68 and an American Shoulder and Elbow Surgeons score of 52.71, reflecting substantial improvements in both shoulder function and pain management. Notably, the Visual Analog Scale scores decreased significantly, from a preoperative average of 6.57 to a postoperative average of 3.79. This reduction in pain intensity indicates that patients experienced a marked alleviation of discomfort following the surgical intervention.Conclusion: Modular tumor prosthesis represents a reliable and effective treatment option for proximal humerus tumors. Although low infection and recurrence rates were noted, further research with larger sample sizes and longer follow-up is necessary to fully understand the long-term durability of the prosthesis and its potential complications, particularly in younger, more active patients.
- Open Access
- 17 March 2026
- Published by Joint Diseases and Related Surgery in Joint Diseases and Related Surgery
- Vol. 37 (2) , 531-542
Fibrous dysplasia: Clinical features, deformities, management, and outcomes
The aim of this study was to evaluate the rate of proximal femoral involvement and the incidence of shepherd's crook deformity in patients with fibrous dysplasia (FD) and to identify possible factors associated with the development of shepherd's crook deformity. Between January 1990 and December 2022, a total of 158 consecutive patients (78 males, 80 females; mean age: 23.8 ± 15.0 years; range, 3 to 71 years) diagnosed with FD were retrospectively analyzed. Presenting symptoms, lesion location, radiological findings, treatment modalities, development of deformity, postoperative complications, and the need for secondary surgery were recorded. The mean follow-up was 64.2 ± 38.4 (range, 24 to 210) months. Among the patients, 125 had monostotic and 33 had polyostotic lesions. Of the 215 lesions identified, 83 were treated surgically, while 132 were managed with clinical observation. Shepherd's crook deformity was observed in nine of 75 proximal femoral lesions. The deformity was significantly more common in polyostotic than in monostotic lesions (25.0% vs. 5.9% respectively; p = 0.026). McCune-Albright syndrome (MAS) was present in two patients, both exhibiting shepherd's crook deformity, whereas the rate was 9.6% among patients without MAS. Valgus osteotomy was performed in all nine patients with shepherd's crook deformity, improving the mean neck-shaft angle from 90.5° (range, 85 to 105°) preoperatively to 125.6° (range, 120 to 130°) postoperatively. In six of these patients, no marked loss in the postoperative neck-shaft angle was observed, while three patients required secondary surgery due to recurrence of the deformity. Most lesions can be managed successfully with observation, while surgery is indicated for the eradication of symptomatic lesions, prevention of pathological fractures, and correction of deformities. Shepherd's crook deformity seems to be more common in patients with polyostotic lesions and MAS. Although valgus osteotomy can achieve radiographic improvement, recurrence of deformity and the need for multiple surgeries are not uncommon.
- 17 March 2026
- Published by Joint Diseases and Related Surgery in Joint Diseases and Related Surgery
- Vol. 37 (2) , 531-542
Open AccessFibrous dysplasia: Clinical features, deformities, management, and outcomes
The aim of this study was to evaluate the rate of proximal femoral involvement and the incidence of shepherd's crook deformity in patients with fibrous dysplasia (FD) and to identify possible factors associated with the development of shepherd's crook deformity. Between January 1990 and December 2022, a total of 158 consecutive patients (78 males, 80 females; mean age: 23.8 ± 15.0 years; range, 3 to 71 years) diagnosed with FD were retrospectively analyzed. Presenting symptoms, lesion location, radiological findings, treatment modalities, development of deformity, postoperative complications, and the need for secondary surgery were recorded. The mean follow-up was 64.2 ± 38.4 (range, 24 to 210) months. Among the patients, 125 had monostotic and 33 had polyostotic lesions. Of the 215 lesions identified, 83 were treated surgically, while 132 were managed with clinical observation. Shepherd's crook deformity was observed in nine of 75 proximal femoral lesions. The deformity was significantly more common in polyostotic than in monostotic lesions (25.0% vs. 5.9% respectively; p = 0.026). McCune-Albright syndrome (MAS) was present in two patients, both exhibiting shepherd's crook deformity, whereas the rate was 9.6% among patients without MAS. Valgus osteotomy was performed in all nine patients with shepherd's crook deformity, improving the mean neck-shaft angle from 90.5° (range, 85 to 105°) preoperatively to 125.6° (range, 120 to 130°) postoperatively. In six of these patients, no marked loss in the postoperative neck-shaft angle was observed, while three patients required secondary surgery due to recurrence of the deformity. Most lesions can be managed successfully with observation, while surgery is indicated for the eradication of symptomatic lesions, prevention of pathological fractures, and correction of deformities. Shepherd's crook deformity seems to be more common in patients with polyostotic lesions and MAS. Although valgus osteotomy can achieve radiographic improvement, recurrence of deformity and the need for multiple surgeries are not uncommon.
- Open Access
- 25 May 2024
- Published by Springer Nature in Archives of orthopaedic and trauma surgery
- Vol. 144 (7) , 2927-2934
Brown tumors: Retrospective analysis of 26 cases
Introduction: Brown tumors are reactive osteolytic lesions caused by hyperparathyroidism. These rare lesions are non-neoplastic processes that result from bone resorption. The purpose of this study was to retrospectively review a 34-year experience with brown tumors in our institution. Materials and methods: We retrospectively analyzed the records of 26 consecutive patients with brown tumor who were treated in our institution between May 1988 and October 2020, with a mean follow-up of 36,1 months. Results: 17 male (65,4%) and 9 female (34,6%) patients with a mean age of 41,6 were included in the study. Localized bone pain was present in 13 cases (50,0%) as the first presenting symptom. 3 patients (11,5%) presented with diffuse bone pain. 7 patients (26,9%) were diagnosed with brown tumor while being investigated for pathological fractures. The other 3 patients (11,5%) were diagnosed while being evaluated for hypercalcemia symptoms. 7 patients (26,9%) had solitary lesions, while 19 patients (73,1%) had multiple lesions. Pelvis, femur, ribs, tibia, proximal humerus and mandible were the most common sites of localization. 23 patients (88,5%) were diagnosed with primary hyperparathyroidism, while the other 3 patients (11,5%) had secondary hyperparathyroidism. A total of the 65 lesions, 23 (35.4%) underwent orthopedic surgery, and 42 (64.6%) were followed up conservatively after parathyroidectomy. Orthopedic surgery was performed in 21 of 26 patients, the other 5 cases were followed up conservatively. Intralesional curettage was performed in 19 cases (82,6%). The resulting cavity was filled with bone cement in 11 cases (47,8%). Bone grafting was applied in 8 cases (34,8%). No recurrence was observed in any of the patients. Conclusion: The diagnosis of brown tumor begins with clinical suspicion. Endocrinology and general surgery consultation is important before surgery. Treatment of brown tumors requires a multidisciplinary approach.
- 25 May 2024
- Published by Springer Nature in Archives of orthopaedic and trauma surgery
- Vol. 144 (7) , 2927-2934
Open AccessBrown tumors: Retrospective analysis of 26 cases
Introduction: Brown tumors are reactive osteolytic lesions caused by hyperparathyroidism. These rare lesions are non-neoplastic processes that result from bone resorption. The purpose of this study was to retrospectively review a 34-year experience with brown tumors in our institution. Materials and methods: We retrospectively analyzed the records of 26 consecutive patients with brown tumor who were treated in our institution between May 1988 and October 2020, with a mean follow-up of 36,1 months. Results: 17 male (65,4%) and 9 female (34,6%) patients with a mean age of 41,6 were included in the study. Localized bone pain was present in 13 cases (50,0%) as the first presenting symptom. 3 patients (11,5%) presented with diffuse bone pain. 7 patients (26,9%) were diagnosed with brown tumor while being investigated for pathological fractures. The other 3 patients (11,5%) were diagnosed while being evaluated for hypercalcemia symptoms. 7 patients (26,9%) had solitary lesions, while 19 patients (73,1%) had multiple lesions. Pelvis, femur, ribs, tibia, proximal humerus and mandible were the most common sites of localization. 23 patients (88,5%) were diagnosed with primary hyperparathyroidism, while the other 3 patients (11,5%) had secondary hyperparathyroidism. A total of the 65 lesions, 23 (35.4%) underwent orthopedic surgery, and 42 (64.6%) were followed up conservatively after parathyroidectomy. Orthopedic surgery was performed in 21 of 26 patients, the other 5 cases were followed up conservatively. Intralesional curettage was performed in 19 cases (82,6%). The resulting cavity was filled with bone cement in 11 cases (47,8%). Bone grafting was applied in 8 cases (34,8%). No recurrence was observed in any of the patients. Conclusion: The diagnosis of brown tumor begins with clinical suspicion. Endocrinology and general surgery consultation is important before surgery. Treatment of brown tumors requires a multidisciplinary approach.
- Open Access
- 26 April 2024
- Published by Joint Diseases and Related Surgery in Joint Diseases and Related Surgery
- Vol. 35 (2) , 377-385
Chondromyxoid fibroma: A retrospective evaluation of 31 cases
Joint Diseases and Related Surgery (JDRS), the official journal of the Turkish Joint Diseases Foundation, is an international, peer-reviewed, immediate open access journal. All published articles in JDRS has been free for everyone, without embargo, since 1990.
- 26 April 2024
- Published by Joint Diseases and Related Surgery in Joint Diseases and Related Surgery
- Vol. 35 (2) , 377-385
Open AccessChondromyxoid fibroma: A retrospective evaluation of 31 cases
Joint Diseases and Related Surgery (JDRS), the official journal of the Turkish Joint Diseases Foundation, is an international, peer-reviewed, immediate open access journal. All published articles in JDRS has been free for everyone, without embargo, since 1990.
- 15 August 2023
- Published by Bilimsel Tip Publishing House in TOTBID Dergisi
- Vol. 22 (5) , 484-487
Diagnosis and treatment principles for intra-articular soft tissue sarcomas
- 15 August 2023
- Published by Bilimsel Tip Publishing House in TOTBID Dergisi
- Vol. 22 (5) , 484-487
Diagnosis and treatment principles for intra-articular soft tissue sarcomas
- Open Access
- 31 July 2023
- Published by Galenos Yayinevi in Journal of Ankara University Faculty of Medicine
- Vol. 76 (2) , 159-162
Lipoma Arborescens: A Rare Cause of Synovial Mass of the Knee at Pediatric Age with 10 Year Follow-up
- 31 July 2023
- Published by Galenos Yayinevi in Journal of Ankara University Faculty of Medicine
- Vol. 76 (2) , 159-162
Open AccessLipoma Arborescens: A Rare Cause of Synovial Mass of the Knee at Pediatric Age with 10 Year Follow-up
- Open Access
- 6 January 2023
- Published by Joint Diseases and Related Surgery in Joint Diseases and Related Surgery
- Vol. 34 (1) , 207-214
Prognostic factors in endometrial cancer patients with bone metastasis
Joint Diseases and Related Surgery (JDRS), the official journal of the Turkish Joint Diseases Foundation, is an international, peer-reviewed, immediate open access journal. All published articles in JDRS has been free for everyone, without embargo, since 1990.
- 6 January 2023
- Published by Joint Diseases and Related Surgery in Joint Diseases and Related Surgery
- Vol. 34 (1) , 207-214
Open AccessPrognostic factors in endometrial cancer patients with bone metastasis
Joint Diseases and Related Surgery (JDRS), the official journal of the Turkish Joint Diseases Foundation, is an international, peer-reviewed, immediate open access journal. All published articles in JDRS has been free for everyone, without embargo, since 1990.